Updates on mouse models of Alzheimer’s disease
Molecular Neurodegeneration,
Год журнала:
2024,
Номер
19(1)
Опубликована: Март 11, 2024
Abstract
Alzheimer’s
disease
(AD)
is
the
most
common
neurodegenerative
in
United
States
(US).
Animal
models,
specifically
mouse
models
have
been
developed
to
better
elucidate
mechanisms
and
test
therapeutic
strategies
for
AD.
A
large
portion
of
effort
field
was
focused
on
developing
transgenic
(Tg)
through
over-expression
genetic
mutations
associated
with
familial
AD
(FAD)
patients.
Newer
generations
knock-in
(KI)/knock-out
(KO)
or
CRISPR
gene
editing
technologies,
both
sporadic
risk
genes
hope
more
accurately
model
proteinopathies
without
human
brains.
In
this
review,
we
summarized
phenotypes
a
few
commonly
used
as
well
newly
translational
research
laboratories
including
presence
absence
key
pathological
features
such
amyloid
tau
pathology,
synaptic
neuronal
degeneration
cognitive
behavior
deficits.
addition,
advantages
limitations
these
elaborated
along
discussions
any
sex-specific
features.
More
importantly,
omics
data
from
available
analyzed
categorize
molecular
signatures
each
reminiscent
brain
changes,
guide
future
selection
suitable
specific
questions
be
addressed
field.
Язык: Английский
Lost in translation: Inconvenient truths on the utility of mouse models in Alzheimer’s disease research
eLife,
Год журнала:
2024,
Номер
13
Опубликована: Сен. 27, 2024
The
recent,
controversial
approval
of
antibody-based
treatments
for
Alzheimer’s
disease
(AD)
is
fueling
a
heated
debate
on
the
molecular
determinants
this
condition.
discussion
should
also
incorporate
critical
revision
limitations
preclinical
mouse
models
in
advancing
our
understanding
AD.
We
critically
discuss
animal
models,
stressing
need
careful
consideration
how
experiments
are
designed
and
results
interpreted.
identify
shortcomings
AD
to
recapitulate
complexity
human
disease.
dissect
these
issues
at
quantitative,
qualitative,
temporal,
context-dependent
levels.
argue
that
based
oversimplistic
assumptions
proposed
by
amyloid
cascade
hypothesis
(ACH)
fail
account
multifactorial
nature
By
shedding
light
constraints
current
experimental
tools,
review
aims
foster
development
implementation
more
clinically
relevant
tools.
While
we
do
not
rule
out
role
call
alternative
approaches
be
explored
and,
most
importantly,
re-evaluation
ACH.
Язык: Английский
Humanized rodent models of neurodegenerative diseases and other brain disorders
Neuroscience & Biobehavioral Reviews,
Год журнала:
2025,
Номер
unknown, С. 106112 - 106112
Опубликована: Март 1, 2025
Язык: Английский
Strategies to dissect microglia-synaptic interactions during aging and in Alzheimer's disease
Neuropharmacology,
Год журнала:
2024,
Номер
254, С. 109987 - 109987
Опубликована: Май 3, 2024
Язык: Английский
Advancements in Immunity and Dementia Research: Highlights from the 2023 AAIC Advancements: Immunity Conference
Alzheimer s & Dementia,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 18, 2024
Abstract
The
immune
system
is
a
key
player
in
the
onset
and
progression
of
neurodegenerative
disorders.
While
brain
resident
cell‐mediated
neuroinflammation
peripheral
cell
(eg,
T
cell)
infiltration
into
have
been
shown
to
significantly
contribute
Alzheimer's
disease
(AD)
pathology,
nature
extent
responses
context
AD
related
dementias
(ADRD)
remain
unclear.
Furthermore,
roles
driving
ADRD
pathology
incompletely
elucidated.
In
March
2023,
Association
convened
International
Conference
(AAIC),
Advancements:
Immunity,
discuss
ADRD.
A
wide
range
topics
were
discussed,
such
as
animal
models
that
replicate
human
immune‐related
biomarkers
clinical
trials,
lessons
from
other
fields
describing
neurodegeneration.
This
manuscript
presents
highlights
conference
outlines
avenues
for
future
research
on
immunity
Highlights
plays
central
role
pathogenesis
disease.
exerts
numerous
effects
throughout
amyloid‐beta,
tau,
pathways.
2023
AAIC,
encouraged
discussions
collaborations
understanding
system.
Язык: Английский